Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 501–600 of 1,003
Sindet-Pedersen, C., Staerk, L., Pallisgaard, J. L., Gerds, T. A., Berger, J. S., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy021 · Cited by 30
Singer, A. J., Quinn, A., Dasgupta, N., & Thode, H. C. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.09.028 · Cited by 33
Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J. J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R., Wyatt, H., & Piazza, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00045 · Cited by 30
“We hypothesize that the 6-month rate of major and clinicallyrelevant, non-major bleeding in these patients will be ≤3% (31).”
BackgroundShaya, S. A., Saldanha, L. J., Vaezzadeh, N., Zhou, J., Ni, R., & Gross, P. L. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13182 · Cited by 31
Schellong, S., Kakkar, A. K., Eriksson, H., Feuring, M., Kreuzer, J., Fraessdorf, M., Schulman, S., & Goldhaber, S. Z. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0271 · Cited by 34
“Edoxaban in HOKUSAI-VTE (7) and apixaban in AMPLIFY (8) were non-inferior compared with warfarin for the efficacy endpoint of preventing recurrent VTE.”
BackgroundAlzghari, S. K., Seago, S. E., Garza, J. E., Hashimie, Y., Baty, K. A., Evans, M. F., Shaver, C. N., & Herrington, J. D. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217718382 · Cited by 31
Practical Considerations for Use of Direct Oral Anticoagulants in Children
Whitworth, H., & Raffini, L. J. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.860369 · Cited by 31
Diretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia – 2024
Gualandro, D. M., Fornari, L. S., Caramelli, B., Abizaid, A., Gomes, B. R., Tavares, C. A. M., Fernandes, C. J. C. D. S., Polanczyk, C. A., Jardim, C., Vieira, C. L. Z., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240590 · Cited by 43
Harenberg, J., Du, S., Weiss, C., Krämer, R., Hoppensteadt, D., & Walenga, J. M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12547 · Cited by 29
Consistency of safety profile of new oral anticoagulants in patients with renal failure
Lega, J., Bertoletti, L., Gremillet, C., Boissier, C., Mismetti, P., & Laporte, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12486 · Cited by 29
Cove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 33
Goto, M., Miura, S., Suematsu, Y., Idemoto, Y., Takata, K., Imaizumi, S., Uehara, Y., & Saku, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.212 · Cited by 31
Renlund, H., Svensson, P. J., Själander, A., & Sandén, P. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0489 · Cited by 30
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Song, A. B., Rosovsky, R. P. G., Connors, J. M., & Al-Samkari, H. T. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s132556 · Cited by 29
Bixby, A. L., Shaikh, S. A., Naik, A. S., Cotiguala, L., McMurry, K. A., Samaniego, M., Marshall, V. D., & Park, J. M. (2020) · Transplant International · doi:10.1111/tri.13599 · Cited by 29
Assessment of coronary artery disease during hospitalization for cancer treatment
Mrotzek, S. M., Lena, A., Hadzibegovic, S., Ludwig, R., Al‐Rashid, F., Mahabadi, A. A., Mincu, R. I., Michel, L., Johannsen, L., Hinrichs, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01719-5 · Cited by 35
Huenerbein, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Deventer, E., Engelhardt, C., Grießhammer, M., & Wille, K. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04350-6 · Cited by 29
Backus, B. E., Beyer‐Westendorf, J., Body, R. M., Lindner, T., Möckel, M., Sehgal, V., Parry‐Jones, A., Seiffge, D. J., & Gibler, B. (2023) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001049 · Cited by 33
Barmparas, G., Kobayashi, L. M., Dhillon, N. K., Patel, K., Ley, E. J., Coimbra, R. S. M., & Margulies, D. R. (2018) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2018.10.016 · Cited by 29
Kang, J. M., Park, K. H., Ahn, S., Cho, S., Han, A., Lee, T., Jung, I. M., Kim, J. Y., & Min, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-56887-w · Cited by 29
Alfirevic, A., Downing, J., Daras, K., Comerford, T., Pirmohamed, M., & Barr, B. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033357 · Cited by 30
The relationship between DOAC levels and clinical outcomes: The measures tell the tale
Toorop, M. M. A., Lijfering, W. M., & Scheres, L. J. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15104 · Cited by 32
“Because patients at extremes of body weight were underrepresented in DOAC clinical trials (<20% weighed > 90 to 100 kg and < 15% weighed < 50 kg),[4,5,25] and randomized trials of DOACs for these specific patient groups are currently unavailable, the current recommendation of DOAC use in patients weighing > 120 kg or…”
BackgroundPreblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1099412 · Cited by 28
“[38–40] There is also wide variation in treatment duration, the proportion of unprovoked/provoked VTE cases, the number of PE patients and the disease extensiveness that were studied in the Phase 3 clinical trials.”
BackgroundDirect oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 28
Moustafa, F., Pesavento, R., Micco, P. D., González‐Martínez, J., Quintavalla, R., Peris, M. L., Porras, J. A., Falvo, N., Baños, P., Monréal, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.781 · Cited by 30
Anticoagulation prescribing patterns in patients with cancer
Xiang, E., Ahuja, T., Raco, V., Cirrone, F., Green, D., & Papadopoulos, J. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1558-1 · Cited by 32
Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?
Konstantinides, S., & Meyer, G. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02340-0 · Cited by 34
“Regardless of whether parenteral heparin is used over the first few hours or days after acute PE, the 2019 Guidelines now recommend that, when it is decided to start oral anticoagulation, a NOAC should be preferred to a vitamin K antagonist (VKA) [8].”
MethodInfluentialLutsey, P. L., Walker, R. F., MacLehose, R. F., Norby, F. L., Evensen, L. H., Alonso, Á., & Zakai, N. A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020428 · Cited by 31
Bertoletti, L., Gusto, G., Khachatryan, A., Quignot, N., Chaves, J., Moniot, A., & Mokgokong, R. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1731-3922 · Cited by 32
“that apixaban was noninferior to conventional therapy for risk of recurrent VTE or VTErelated death.(31) Similarly, a US claims database study showed that major bleeding, clinically relevant non-major bleeding, and recurrent VTE were all lower with apixaban than warfarin, even though patients in the current study were…”
MethodJeong, I., Alotaibi, M., Fernandes, T. M., Kim, S., Kerr, K. M., Yang, J. Z., Pretorius, V. G., Madani, M. M., & Kim, N. H. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12110 · Cited by 28
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Turpie, A. G. G., Farjat, A. E., Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Goto, S., Angchaisuksiri, P., Kayani, G., Lópes, R. D., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.016 · Cited by 28
Self-citationHosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.036 · Cited by 30
Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents
Bölek, H., & Ürün, Y. (2023) · Cancer · doi:10.1002/cncr.34937 · Cited by 30
Busse, L. W., & Vourlekis, J. S. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.03.006 · Cited by 29
Palareti, G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.02.002 · Cited by 29
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Agnelli, G., & Becattini, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00164714 · Cited by 33
Self-citationA Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 29
Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy
Patel, S. I., Cherington, C. C., Scherber, R. M., Barr, K., McLemore, R. Y., Morisky, D. E., Cha, S., Mookadam, F., & Shamoun, F. E. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.002 · Cited by 31
Bertoletti, L., Benhamou, Y., Béjot, Y., Maréchaux, S., Cheggour, S., Aleil, B., Lellouche, N., Dillinger, J., & Delluc, A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.002 · Cited by 30
Ašić, A., Marjanović, D., Mirat, J., & Primorac, D. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0092 · Cited by 34
Aloi, K. G., Fierro, J. J., Stein, B. J., Lynch, S. M., & Shapiro, R. J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854578 · Cited by 28
Harel, Z., Sood, M. M., & Perl, J. M. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000098 · Cited by 29
“The AMPLIFY [30] trial compared apixaban with warfarin in the management of DVT/PE among a subset of 338 patients with stage 3 or greater CKD.”
BackgroundMethodAgeno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Haupt, V., Schneider, J., & Turpie, A. G. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-16 · Cited by 29
Lam, E., Bashir, B., Chaballa, M., & Kraft, W. K. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1637733 · Cited by 27
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
Riva, N., & Ageno, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030743 · Cited by 29
Ethnoracial variations in venous thrombosis: Implications for management, and a call to action
Xu, Y., Siegal, D. M., & Anand, S. S. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15140 · Cited by 28
Vlazny, D. T., Pasha, A. K., Kuczmik, W., Wysokiński, W. E., Bartlett, M. A., Houghton, D. E., Casanegra, A. I., Daniels, P. R., Froehling, D. A., White, L. J., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15416 · Cited by 30
Direct oral anticoagulants for use in paediatrics
Jaffray, J., & Young, G. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00343-6 · Cited by 29
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2714 · Cited by 28
“The risk of ICH was 50% lower for apixaban.(16) Other trials had insufficient events or reported them differently.”
BackgroundZaky, M. F., Megahed, M. A., Hammady, T. M., Gad, S., Ghorab, M. M., & El‐Say, K. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010080 · Cited by 27
“5 mg twice daily up to 5 mg twice daily [13,14].”
BackgroundSuccinct Review of the New VTE Prevention and Management Guidelines
Pollak, A. W., & McBane, R. D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.015 · Cited by 28
Diagnose und Management der akuten pulmonalen Embolie: ESC-Leitlinien 2014
Saar, J. A., & Maack, C. (2015) · Herz · doi:10.1007/s00059-015-4378-0 · Cited by 30
Yamashita, Y., Morimoto, T., Toyota, T., Shiomi, H., Makiyama, T., Ono, K., & Kimura, T. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.04.008 · Cited by 30
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Sulaiman, K. A. A., Hafiz, A. M., Badreldin, H. A., Korayem, G. B., Alsuwayyid, F., Alrashidi, A., Alhijris, M., Almutairi, F. F., Alharthi, F., Alghamdi, S. A., et al. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221099893 · Cited by 26
Management of intermediate‐risk pulmonary embolism: uncertainties and challenges
Klok, F. A., Meyer, G., & Konstantinides, S. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12612 · Cited by 27
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism
Goldhaber, S. Z., Kakkar, A. K., Kearon, C., Eriksson, H., Kreuzer, J., Feuring, M., Hantel, S., Friedman, J. E., Schellong, S., Schulman, S., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0319 · Cited by 26
“Major bleeding and clinically relevant non-major bleeding events were significantly fewer among patients receiving apixaban than those receiving conventional therapy in the AMPLIFY trial (13).”
BackgroundAgeno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Monje, D., Schneider, J., van Eickels, M., Gebel, M., & Turpie, A. G. G. (2017) · TH Open · doi:10.1055/s-0037-1603924 · Cited by 26
Literature review of distal deep vein thrombosis
Skeik, N., Smith, J. E., Jensen, J. D., Nowariak, M. E., Manunga, J. M., & Mirza, A. K. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.01.018 · Cited by 28
Klok, F. A., Toenges, G., Mavromanoli, A. C., Barco, S., Ageno, W., Bouvaist, H., Brodmann, M., Cuccia, C., Couturaud, F., Dellas, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00203-9 · Cited by 31
Perino, A. C., Fan, J., Schmitt, S. K., Guo, J. D., Hlavacek, P., Din, N., Kothari, M., Pundi, K. N., Russ, C., Emir, B., et al. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008005 · Cited by 26
“To remove anthropometric outliers, we excluded all (1) weight measurements <34.”
InfluentialShu, L., Bakradze, E., Omran, S. S., Giles, J. A., Amar, J. Y., Henninger, N., Elnazeir, M., Liberman, A. L., Moncrieffe, K., Rotblat, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201122 · Cited by 30
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
“The efficacy of apixaban for VTE treatment, using a single drug approach, has recently been investigated in the AMPLIFY trial [77].”
DVT Management and Outcome Trends, 2001 to 2014
Morillo, R., Jiménez, D., Arregui, M. Á. A., Mastroiacovo, D., Wells, P. S., Samperiz, A. L., de Sousa, M. S., Muriel, A., Yusen, R. D., Monréal, M., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.03.046 · Cited by 26
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
Peacock, W. F., Rafique, Z., & Singer, A. J. (2016) · Emergency Medicine International · doi:10.1155/2016/1781684 · Cited by 28
“…were noninferior for the treatment of acute symptomatic VTE and were associated with significantly decreased bleeding risks compared with standard therapy (LMWH or unfractionated heparin followed by treatment with an overlapping VKA (warfarin or acenocoumarol); see Supplemental Table 2) [29–33].”
Zhang, Z., Zhai, Z., Yang, Y., Wan, J., Xie, W., Zhu, J., Shen, Y. H., & Wang, C. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1473-5 · Cited by 26
“7% within 6–12 months) [13, 18, 19], yet similar with the other registry and observed studies (2.”
ResultKalathottukaren, M. T., Haynes, C. A., & Kizhakkedathu, J. N. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0413-4 · Cited by 26
Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients
Lutsey, P. L., Horvath, K. J., Fullam, L., Moll, S., Rooney, M. R., Cushman, M., & Zakai, N. A. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1625985 · Cited by 28
What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Beyer‐Westendorf, J. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.034 · Cited by 28
DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA
Serrao, A., Lucani, B., Mansour, D., Ferretti, A., Baldacci, E., Santoro, C., Foà, R., & Chistolini, A. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.044 · Cited by 27
“Median FU during DOACs (months) 29 (6-66)”
Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome
Kokosi, M. A., Lams, B., & Agarwal, S. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.06.001 · Cited by 27
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 34
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation
Jaffer, I., Fredenburgh, J. C., Stafford, A. R., Whitlock, R. P., & Weitz, J. I. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.10.091 · Cited by 26
Self-citationEvaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Nederpelt, C. J., Naar, L., Sylvester, K. W., Barra, M. E., Roberts, R. J., Velmahos, G. C., Kaafarani, H. M. A., Rosenthal, M. G., & King, D. R. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15031 · Cited by 26
Use of direct‐acting oral anticoagulants in solid organ transplantation: A systematic review
Bixby, A. L., Lichvar, A. B., Salerno, D. M., & Park, J. M. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2485 · Cited by 26
How, J., Story, C. M., Ren, S., Neuberg, D. S., Rosovsky, R. P. G., Hobbs, G. S., & Connors, J. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00566-5 · Cited by 27
Mandt, S. R., Thadathil, N., Klem, C., Russ, C., McNamee, P. L., Stigge, K., & Cheng, D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00664-2 · Cited by 28
“The AMPLIFY trial compared the efficacy and safety of apixaban with low-molecular-weight heparin (LMWH) followed by warfarin (i.e., a conventional therapy) [27].”
InfluentialApixaban Use Among Patients With Severe Renal Impairment
Deal, E. N., Pope, H. E., & Ross, W. R. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014554446 · Cited by 25
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.009 · Cited by 26
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Self-citationPulmonary embolism response teams
Serhal, M., Haddadin, I., Heresi, G. A., Hornacek, D., Shishehbor, M. H., & Bartholomew, J. R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1498-9 · Cited by 28
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Covert, K. L., & Branam, D. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa059 · Cited by 26
“The AMPLIFY trial included 225 patients (9% of the total) with a body weight of ≤60 kg and was not powered to detect safety or efficacy differences in this population.(7) The study by Upreti and colleagues(14) demonstrated 27% and 20% higher mean apixaban C max and AUC values, respectively, in patients weighing 50 kg…”
BackgroundMethodTreatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Shaikh, F., Wynne, R. M., Castelino, R. L., Inglis, S. C., & Ferguson, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.732828 · Cited by 26
Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration
Diavati, S., Sagris, Μ., Terentes-Printzios, D. G., & Vlachopoulos, C. V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211111150705 · Cited by 32
Williams, B., Saseen, J. J., Trujillo, T. C., & Palkimas, S. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02587-0 · Cited by 28
Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.170 · Cited by 29
Amin, A., & Marrs, J. C. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615601492 · Cited by 28
“Extended anticoagulation (>3 months) is beneficial in patients with VTE, and the direct OACs have demonstrated noninferiority in the reduction of recurrent venous thromboembolic events versus standard therapy.(26,27,29,32,33,36,38,39) Phase II dose-finding studies of anticoagulants usually focus on safety outcomes to…”
BackgroundMethodRecent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
Novel anticoagulants and antiplatelet agents; a guide for the urologist
Ellis, G., Camm, A. J., & Datta, S. N. (2015) · British Journal of Urology · doi:10.1111/bju.13131 · Cited by 26
Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
Franco, L., Becattini, C., Vanni, S., Sbrojavacca, R., Nitti, C., Manina, G., Masotti, L., Pomero, F., Cattinelli, S., Cappelli, R., et al. (2018) · Blood transfusion · doi:10.2450/2017.0335-16 · Cited by 26
Self-citationLópez-Núñez, J. J., Pérez-Andrés, R., Micco, P. D., Schellong, S., Cuervo, C. G., Sahuquillo, J., Ciammaichella, M. M., Morales, M., Bosevski, M., Monréal, M., et al. (2019) · TH Open · doi:10.1055/s-0039-1683970 · Cited by 25
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
How I treat obese patients with oral anticoagulants
Wang, T., & Carrier, M. (2020) · Blood · doi:10.1182/blood.2019003528 · Cited by 29
Cerdà, P., Becattini, C., Iriarte, A., Cortés-Hernández, J., Corbella, X., & Riera‐Mestre, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.012 · Cited by 25
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis
Oldham, M., Palkimas, S., & Hedrick, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211047433 · Cited by 25
“001 NASH, n (%) 6 (9) 7 (22) NS HCV, n (%) 8 (12) 3 (10) NS Cardiac cirrhosis, n (%) 5 (7) 5 (16) NS HCC, n (%) 6 (9) 0 0.”
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.